Acalabrutinib Monotherapy in Patients With Ibrutinib Intolerance: Results From the Phase 1/2 ACE-CL-001 Clinical Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 16
页数：3
相关论文
共 50 条
  • [31] Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
    Gouill, Steven Le
    ugosz-Danecka, Monika
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Smith, Stephen D.
    Doorduijn, Jeanette K.
    Panizo, Carlos
    Shah, Bijal D.
    Davies, Andrew J.
    Eek, Richard
    Jacobsen, Eric
    Kater, Arnon P.
    Robak, Tadeusz
    Jain, Preetesh
    Calvo, Roser
    Tao, Lin
    Wang, Michael
    HAEMATOLOGICA, 2024, 109 (01) : 343 - 350
  • [32] Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 6 - 8
  • [33] Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
    Do-Youn Oh
    Maria Alsina Maqueda
    David I. Quinn
    Peter J. O’Dwyer
    Ian Chau
    Sun Young Kim
    Ignacio Duran
    Daniel Castellano
    Jordan Berlin
    Begona Mellado
    Stephen K. Williamson
    Keun-Wook Lee
    Francisca Marti
    Paul Mathew
    Muhammad Wasif Saif
    Ding Wang
    Elizabeth Chong
    Jacqueline Hilger-Rolfe
    James P. Dean
    Hendrik-Tobias Arkenau
    BMC Cancer, 23
  • [34] Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
    Oh, Do-Youn
    Maqueda, Maria Alsina
    Quinn, David I.
    O'Dwyer, Peter J.
    Chau, Ian
    Kim, Sun Young
    Duran, Ignacio
    Castellano, Daniel
    Berlin, Jordan
    Mellado, Begona
    Williamson, Stephen K.
    Lee, Keun-Wook
    Marti, Francisca
    Mathew, Paul
    Saif, Muhammad Wasif
    Wang, Ding
    Chong, Elizabeth
    Hilger-Rolfe, Jacqueline
    Dean, James P.
    Arkenau, Hendrik-Tobias
    BMC CANCER, 2023, 23 (01)
  • [35] NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY
    Liedtke, Michaela
    Comenzo, Raymond
    Landau, Heather
    Sanchorawala, Vaishali
    Weiss, Brendan
    Zonder, Jeffrey
    Walling, Jackie
    Kinney, Gene
    Koller, Martin
    Schenk, Dale B.
    Guthrie, Spencer
    Liu, Enchi
    Gertz, Morie
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 825 - 825
  • [36] Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Lampson, Benjamin L.
    Tyekucheva, Svitlana
    Crombie, Jennifer L.
    Kim, Austin I.
    Merryman, Reid W.
    Lowney, Jessica
    Montegaard, Josie
    Patterson, Victoria
    Jacobson, Caron A.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Arnason, Jon E.
    Armand, Philippe
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2019, 134
  • [37] Impact of NEOD001 on Neuropathy in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From the Expansion Phase of a Phase 1/2 Study
    Liedtke, Michaela
    Comenzo, Raymond L.
    Landau, Heather
    Sanchorawala, Vaishali
    Weiss, Brendan M.
    Zonder, Jeffrey
    Walling, Jackie
    Kinney, Gene G.
    Koller, Martin
    Schenk, Dale B.
    Guthrie, Spencer D.
    Liu, Enchi
    Gertz, Morie A.
    NEUROLOGY, 2017, 88
  • [38] Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study
    Bartlett, Nancy L.
    Smith, Mitchell R.
    Advani, Ranjana
    Feldman, Tatyana
    Savage, Kerry J.
    Palanca-Wessels, Maria Corinna
    Siddiqi, Tanya
    BLOOD, 2014, 124 (21)
  • [39] Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia
    Opat, Stephen
    Awan, Farrukh T.
    Fogliatto, Laura
    Nikitin, Eugene
    Czerwinski, Joanna
    Alves da Silva, Rodrigo Santucci
    Jujjavarapu, Srinivas
    Samoilova, Olga
    Dartigeas, Caroline
    Tran, Hoa
    de la Serna, Javier
    Banerji, Versha
    Magnano Mayer, Laura
    Hart, Jason
    von Tresckow, Julia
    Poulsen, Christian B.
    Eom, Ki Seong
    Merli, Michele
    John, Ellie
    Munley, Jiefen
    Hakre, Shweta
    Hermann, Richard
    Niemann, Carsten U.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S347 - S347
  • [40] Longitudinal Safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study
    Komrokji, Rami S.
    Gerds, Aaron T.
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    Mesa, Ruben
    Bose, Prithviraj
    Sanabria, Fabian
    Marsousi, Niloufar
    Giuseppi, Ana Carolina
    Jiang, Huijing
    Passamonti, Francesco
    BLOOD, 2023, 142
12345